TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in ...

Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Targeting final FDA approval of YUTREPIATM after expiration of regulatory exclusivity on May 23, 2025 <li /> Advancing pipeline of inha ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Pulmonary Arterial Hypertension (PAH) is an often-overlooked yet life-altering disease that affects thousands globally, requiring lifelong management, rigorous monitoring, and substantial emotional ...

Corporation has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial hypertension market. Cereno Scientific says its lead therapeutic candidate, CS1, ...

Patients with pulmonary arterial hypertension (PAH) can develop several complications with the progression of the disease or as a result of hemodynamic imbalance. Some of these complications include ...